About Chickadee Biomedicines
Chickadee Biomedicines is a private company based in New York, New York, incorporated in 2025 in Delaware. It has reported $1,150,000 raised in two offerings on Form D since June 2026. Its chief executive is Patrick Doyle.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 28, 2026 | Nov 10, 2026 | $1,000,000fully sold | 2 | $500K | Options, Securities on exercise, Simple Agreements for Future Equity (SAFEs) and Issuer's equity securities that would be issued upon conversion of SAFEsRule 506(b) | Form D ↗ |
| Jun 22, 2026 | Jun 25, 2026 | $150,000of $1.0M target | 1 | $150K | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, two offerings | $1,150,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Chickadee Biomedicines's Form D filed Nov 10, 2026.
WL
Weining Lu
Secretary and director
GD
Goran Dolsten
Executive officer, director and promoter
PD
Patrick Doyle
Chief Executive Officer and director
Earlier filings also listed Mikael Dolsten (executive officer, director and promoter, last listed Jun 2026).